The company is raising $500M immediately after a strongly positive clinical data release, a capital need that was not previously telegraphed. This creates a tension: the vopimetostat data is potentially transformative for the stock, but the surprise dilution will pressure the stock near-term. Watch for the pricing announcement (pricing per share set in the final prospectus supplement), a larger discount to market or an upsize would be an incremental negative. The 60-day insider lock-up limits immediate insider selling risk.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 9 $31.56entry
- T+1 · 5mo ago −9.13%α −7.55% · $28.68
- T+5 · 5mo ago +4.25%α +1.83% · $32.90
- T+20 · 4mo ago −4.56%α −6.01% · $30.12
- T+60 · 3mo ago −29.28%α −33.09% · $22.32
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tango Therapeutics is filing a preliminary prospectus supplement for a $500M common stock offering, with an additional $75M underwriter option. The filing comes on the same day the company reported strikingly positive early Phase 1/2 clinical data for vopimetostat + daraxonrasib in MTAP-deleted/RAS-mutant pancreatic cancer (92% ORR, 90% 6-mo PFS in PDAC), which it plans to advance to Phase 3. The large equity raise creates immediate and substantial dilution (~$2.72 tangible book value per share vs. $20.22 stock price), and the preliminary nature of the filing (many terms still blank) signals the offering price is not yet set, the stock may trade down on the surprise dilutive capital need despite the positive clinical readout.
Key Facts
- Tango is offering $500M of common stock via a 424B5 shelf takedown (preliminary prospectus supplement dated June 8, 2026)
- Underwriters have a 30-day option to purchase up to an additional $75M in shares
- Last sale price on June 5, 2026 was $20.22 per share; company had $2.9B market cap
- Net tangible book value as of March 31, 2026 was ~$391.5M, or $2.72 per share, new investors will face immediate and substantial dilution
- The filing is a PRELIMINARY prospectus supplement with all per-share and total dollar amounts left as blanks, pricing has not been set
- On June 8, 2026, the company also reported Phase 1/2 data for vopimetostat + daraxonrasib: 92% ORR (11/12 PDAC patients), 90% 6-month PFS, 100% DCR with no discontinuations
- Company plans to advance vopimetostat + daraxonrasib into a Phase 3 randomized-controlled trial in front-line pancreatic cancer
- Proceeds will fund general corporate purposes, including R&D, pivotal trial expenses, and potential commercialization; management says cash runway extends into 2030
- Existing shareholders (including directors and officers) are subject to a 60-day lock-up from closing
Financial Impact
At $20.22/share, $500M offering implies ~24.7M new shares (~17% dilution on 144.2M shares outstanding). Adding the full $75M greenshoe pushes potential dilution to ~28.4M shares (~20%). Net tangible book value of $2.72/share vs. $20.22 stock price indicates massive dilution for new investors.
Risk Factors
- Massive immediate dilution (~17%+ at current prices) with offering price not yet set, could be a meaningful discount to market
- Preliminary filing has all dollar amounts blank; pricing uncertainty until final prospectus is filed
- Company has no commercial supply agreement in place for Phase 3 daraxonrasib trial, supply chain risk with Revolution Medicines
- Pre-revenue biotech with significant operating losses; offering extends cash runway but increases share count permanently
- Positive Phase 1/2 data is early (n=12 for daraxonrasib arm in PDAC), larger trials may not replicate results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-261771 |
| Document: 0001193125-26-261771-index-headers.html | 0001193125-26-261771 |
| Document: 0001193125-26-261771-index.html | 0001193125-26-261771 |
| Document: 0001193125-26-261771.txt | 0001193125-26-261771 |
Track record
27 reports on TNGX
2 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +20.64% at T+60 after the Jun 9, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
- Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers